Clinical trial · Interventional
Oncoxin® and Quality of Life in Cancer Patients
ONCOXIN® and Quality of Life in Cancer Patients in a Real World Setting Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
It is expected that additional support with certain micronutrients may improve prognosis, decrease the frequency of side effects and complications and maintain high relative dose intensity of anticancer treatments. Food supplement ONCOXIN (ONCX) contains amino acids, vitamins, minerals and biologically active substances of natural origin with high immunostimulatory and antioxidant activity. Present study is a real world experience study intended to evaluate the efficacy of ONCX in cancer patients.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gastric Cancer Stage II | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
| Gastric Cancer Stage III | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
| Non-small Cell Lung Cancer Stage II | Lung Non-Small Cell Carcinoma | CURATED_BROADER | 0.78 |
| Non-small Cell Lung Cancer Stage III | Lung Non-Small Cell Carcinoma | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| ONCOXIN® | Dietary Supplement | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Oncoxin®
- interventionNames
- Dietary Supplement: ONCOXIN®
- type
- NO_INTERVENTION
- label
- Control
Primary outcomes (1)
- measure
- Quality of life improvement
- timeFrame
- 20 days
- description
- The proportion of patients who had an improvement in the QoL corresponding to the minimal clinically important difference (MCID) that any patient was able to feel at Visits 2 in total SDS ESAS (6 points within patient change for improvement)
Secondary outcomes (5)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 50 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: 1. Male and female patients who had signed an informed consent. 2. Males and females aged 50-70 y/o 3. Gastric cancer IIB-IIIC, Non-small cell lung cancer IIB-IIIA 4. R0 surgery 5. Adjuvant chemotherapy (ACT) required, 2nd and further course of ACT, XELOX regimen of ACT for gastric cancer and paclitaxel+carboplatin regimen for non-small cell lung cancer. 6. Body mass index (BMI) ≥ 15, serum albumin ≥ 25 g/l. 7. Eastern Cooperative Oncology Group performance status ≤ 2 Exclusion Criteria: 1. Severe concomitant diseases or conditions that may complicate or make impossible the patient's participation in the study, or make it difficult to interpret the clinical data (including mental disorders, severe infectious and parasitic diseases and intolerability to any of the ONCX components). 2. The patient's family or official relations with a member of staff of the study center. 3. The patient's failure to assess his/her physical and/or emotional condition. 4. The patient's failure to comply with the study requirements. 5. The patient's refusal to participate in the study and pregnancy or lactation.
References
Publications (1)
- DERIVEDKaidarova DR, Kopp MV, Pokrovsky VS, Dzhugashvili M, Akimzhanova ZM, Abdrakhmanov RZ, Babich EN, Bilan EV, Byakhov AV, Gurov SN, Koroleva IA, Mochalova AS, Povaga SS, Raigorodsky MV, Saifullin AS, Sanz E, Petrovskiy FI. Multicomponent nutritional supplement Oncoxin and its influence on quality of life and therapy toxicity in patients receiving adjuvant chemotherapy. Oncol Lett. 2019 Nov;18(5):5644-5652. doi: 10.3892/ol.2019.10868. Epub 2019 Sep 13. PMID 31641390